🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Oral triiodothyronine

    Cardiff Oncology

    Postoperative; Dysfunction Following Cardiac Surgery

    phase 3 small molecule completed

    1 trial

  2. Oxybutinyn Vaginal Ring 4mg

    Teva Pharma GmbH

    Overactive Bladder

    phase 3 small molecule completed

    1 trial

  3. Ozanimod, Ozanimod

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  4. Ozanimod, Ozanimod, Ozanimod

    Bristol-Myers Squibb Australia Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  5. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  6. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide placebo, solution for injection in 1.5 mL pre-filled PDS290 pen injector

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  7. PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -

    Lacuna Pharma Pty Ltd

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  8. PCV21

    Sanofi Pasteur

    Pneumococcal Infections

    phase 3 mab active

    1 trial

  9. PEG-Interferon a-2b + Ribavirin

    Universal Integrated

    Chronic Hepatitis C Infection in HIV-Infected Persons

    phase 3 small molecule completed

    1 trial

  10. PEGASPARGASE

    Pari Pharma GmbH

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    phase 3 small molecule active

    1 trial

  11. PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  12. PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL, MORPHINE

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  13. PF-06651600 Induction Dose

    Pfizer

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  14. PF-07275315 dose 1

    Pfizer

    Moderate to Severe Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  15. PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion

    Pari Pharma GmbH

    patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection

    phase 3 small molecule active

    1 trial

  16. PL1 - Lyophilisate and solvent for solution for injection, sotatercept

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  17. PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule active

    1 trial

  18. PLACEBO OF BELIMUMAB, Benlysta 200 mg solution for injection in pre-filled pen.

    Pari Pharma GmbH

    Adult patients with persistent or chronic immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  19. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  20. PREDNISOLONE , Dupixent 300 mg solution for injection in pre-filled syringe, Placebo matching to dupilumab

    Lacuna Pharma Pty Ltd

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  21. PREDNISOLONE, Placebo for Depemokimab Injection, Placebo for Prednisolone

    GlaxoSmithKline

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  22. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis (UC) or Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  23. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Moderately to severely active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  24. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion, BUDESONIDE

    Takeda

    Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources